Deland D[au] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
1998	2
2002	1
2025	0

Page 1

Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients.

Loh A, Sgouros G, O'Donoghue JA, Deland D, Puri D, Capitelli P, Humm JL, Larson SM, Old LJ, Divgi CR. Loh A, et al. Among authors: deland d. J Nucl Med. 1998 Mar;39(3):484-9. J Nucl Med. 1998. PMID: 9529296 Free article. Clinical Trial.

Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy.

O'Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G. O'Donoghue JA, et al. Among authors: deland d. Cancer Biother Radiopharm. 2002 Aug;17(4):435-43. doi: 10.1089/108497802760363222. Cancer Biother Radiopharm. 2002. PMID: 12396707

Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.

Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ. Divgi CR, et al. Among authors: deland d. Clin Cancer Res. 1998 Nov;4(11):2729-39. Clin Cancer Res. 1998. PMID: 9829736 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year